Cargando…

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)

Once initiated for pulmonary arterial hypertension (PAH), epoprostenol treatment usually needs to be delivered for an indefinite duration. It is possible that some participants could be transitioned from epoprostenol to oral therapies. We retrospectively evaluated eight PAH participants transitioned...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calcaianu, George, Calcaianu, Mihaela, Canuet, Matthieu, Enache, Irina, Kessler, Romain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467933/ https://www.ncbi.nlm.nih.gov/pubmed/28597752 http://dx.doi.org/10.1177/2045893217702401

Ejemplares similares

Hemodynamic profile of pulmonary hypertension (PH) in ARDS
por: Calcaianu, George, et al.
Publicado: (2017)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol
por: Gionfriddo, William J., et al.
Publicado: (2020)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
por: Steele, Peter, et al.
Publicado: (2010)

The Importance of Apneic Events in Obstructive Sleep Apnea Associated with Acute Coronary Syndrome
por: Calcaianu, George, et al.
Publicado: (2019)

Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)—An open-label, single-arm study
por: Mihara, Kazuko, et al.
Publicado: (2018)

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol
por: Izumi, Keiichi, et al.
Publicado: (2022)

Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension
por: Riou, Marianne, et al.
Publicado: (2020)

Mid-term pulmonary sequelae after hospitalisation for COVID-19: The French SISCOVID cohort
por: Calcaianu, George, et al.
Publicado: (2022)

Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Lambert, Olivier, et al.
Publicado: (2012)

Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem
por: Chebib, Nader, et al.
Publicado: (2017)

A Case of Giant Goiter Associated with Airway Stenosis Caused by Long-Term Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension
por: Nishiura, Kazuto, et al.
Publicado: (2023)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)
por: Preston, Ioana R., et al.
Publicado: (2015)

Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension
por: Mori, Ana Laura, et al.
Publicado: (2021)

Symptom phenotypes in pulmonary arterial hypertension: The PAH “symptome”
por: Matura, Lea Ann, et al.
Publicado: (2022)

A diffuse lung emphysema, severe pulmonary hypertension and lack of airflow limitation
por: Faure, Morgane, et al.
Publicado: (2017)

Surgical attitude in premalignant lesions and malignant tumors of the lower lip
por: Calcaianu, N, et al.
Publicado: (2015)

Erratum to: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with a Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
por: Sikirica, Mirko, et al.
Publicado: (2014)

Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application
por: Al-Hilal, Taslim A., et al.
Publicado: (2020)

Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension
por: Preston, Ioana R., et al.
Publicado: (2013)

Cardiovascular Effect of Epoprostenol and Intravenous Cardiac Drugs for Acute Heart Failure on Canine Pulmonary Hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents
por: Yamamoto, Koji, et al.
Publicado: (2014)

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
por: Chida-Nagai, Ayako, et al.
Publicado: (2022)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Case report: High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease
por: Fukasawa, Yoshie, et al.
Publicado: (2023)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Epoprostenol Exposure During Pregnancy
por: Naoum, Emily E., et al.
Publicado: (2023)

Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH
por: McCollister, Deborah, et al.
Publicado: (2016)

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City
por: Sulica, Roxana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_teope685r688ntb72vomtt6j9j